SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001213900-25-043071 from MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)

MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: May 14, 2025 · CIK: 0001874252 · Accession: 0001213900-25-043071

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287249

Date
May 14, 2025
Author
LLC
Form
CORRESP
Company
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Finance F Street, NE Washington, D.C. 20549 Re: Mainz Biomed N.V. Registration Statement on Form F-1 (Registration No. 333-287249)

Dear Ms. Sheppard:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), the undersigned, as placement agent in connection with the above referenced Registration Statement relating to the offer and issuance by the Registrant of certain of its securities, hereby joins the Registrant's request that the effective date of the Registration Statement be accelerated so that it shall be declared effective at 5:00 PM Eastern Time on Thursday, May 15, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that the placement agent has distributed as many copies of the Preliminary Prospectus, dated May 14, 2025, to investors, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

This is to further advise you that the placement agent has and will continue to comply with Rule 15c2-8 of the Securities Exchange Act of 1934, as amended, with regard to the Preliminary Prospectus and any amended Prospectus.

If you require any additional information with respect to this letter, please contact Ali Panjwani of Pryor Cashman LLP at (212) 326-0820.

Very truly
yours,
MAXIM GROUP
LLC

Show Raw Text
CORRESP
 1
 filename1.htm

 MAXIM
GROUP LLC

 300
Park Avenue

 New
York, New York 10022

 May
14, 2025

 VIA
EDGAR

 United
States Securities and Exchange Commission

 Division
of Corporation Finance

 Office
of Finance

 100
F Street, NE

 Washington,
D.C. 20549

 Re:
 Mainz
 Biomed N.V.

 Registration
 Statement on Form F-1 (Registration No. 333-287249)

 Dear
Ms. Sheppard:

 Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), the undersigned, as placement agent
in connection with the above referenced Registration Statement relating to the offer and issuance by the Registrant of certain of its
securities, hereby joins the Registrant's request that the effective date of the Registration Statement be accelerated so that
it shall be declared effective at 5:00 PM Eastern Time on Thursday, May 15, 2025, or as soon thereafter as practicable.

 Pursuant
to Rule 460 under the Act, we wish to advise you that the placement agent has distributed as many copies of the Preliminary Prospectus,
dated May 14, 2025, to investors, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the
preliminary prospectus.

 This
is to further advise you that the placement agent has and will continue to comply with Rule 15c2-8 of the Securities Exchange Act of
1934, as amended, with regard to the Preliminary Prospectus and any amended Prospectus.

 If
you require any additional information with respect to this letter, please contact Ali Panjwani of Pryor Cashman LLP at (212) 326-0820.

 Very truly
 yours,

 MAXIM GROUP
 LLC

 By:
 /s/
 Ritesh M. Veera

 Name:
 Ritesh M. Veera

 Title:
 Co-Head of Investment Banking